GleamWall
中文EN

INDP Indaptus Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1857044 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY20.0%
TTM EPS YoY89.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-180.7%
ROA-70.9%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets66.9%
Debt / equity0.00x
Current ratio—
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.01x
Accruals ratio0.4%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue————————
R&D expense$271,204$363,127$491,134$2.85M$1.52M$2.17M$2.81M$2.48M
SG&A expense$864,663$1.45M$1.67M$5.31M$1.13M$2.29M$1.76M$1.69M
Operating income-$1.14M-$1.81M-$2.16M-$8.16M-$2.65M-$4.46M-$4.57M-$4.17M
Net income-$1.05M-$1.79M-$2.54M-$8.11M-$2.98M-$5.23M-$4.53M-$4.13M
EBITDA———————-$4.17M
EPS (basic)-0.01-0.02-0.23—-2.98-9.09-9.11—
EPS (diluted)-0.01-0.02-0.23—-2.98-9.09-9.11—
Weighted avg. shares (diluted)133.24M116.13M10.96M—997,038574,923497,794—
Balance sheet
Cash & equivalents$26.60M$7.55M$1.50M$8.51M$5.83M$6.16M$3.89M$5.79M
Short-term investments$4.00M$4.00M——————
Current assets——$2.18M$9.31M$6.44M$6.41M$4.96M$6.62M
Total assets$31.21M$11.99M—$9.31M$6.84M$6.84M$5.41M$7.34M
Current liabilities——$932,999$6.16M$2.23M$8.51M$2.61M$3.39M
Total liabilities$20.88M$615,426$932,999$6.16M$2.23M$8.51M$2.61M$3.39M
Shareholders' equity$10.33M$11.37M$1.25M$3.15M$4.61M-$1.67M$2.80M$3.94M
Shares outstanding133.24M133.24M113.24M2.17M1.64M604,96316.03M428,799
Cash flow statement
Operating cash flow-$1.44M-$1.93M-$7.01M-$3.19M-$2.57M-$4.02M-$5.05M-$3.40M
Investing cash flow$0———————
Financing cash flow$20.49M——$5.87M$2.24M$6.28M$3.15M$1.80M
Depreciation & amortization———————$0
Stock-based compensation$8,372-$64,283$227,180$785,814$150,614$180,763$240,891$304,122

Free plan shows the latest 8 periods; Pro shows all 27 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.